Evidence map›Paper›PMID 40699426›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

A Wet Lab Procedure for Gene Fusion Analysis by Targeted RNA Next-Generation Sequencing in Lung Cancer.

Sylvain Lacorre, Maéva Chaumet, Murat Sahin, Emilie Guérin, Paco Derouault, Léa Darnaud, Alexandre Perani, Karine Durand

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sylvain LacorreCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France.
Maéva ChaumetCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France.
Murat SahinCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France.
Emilie GuérinSequencing Platform, CHU Dupuytren, Limoges, France.
Paco DerouaultBioinformatics Platform, CHU Dupuytren, Limoges, France.
Léa DarnaudCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France.
Alexandre PeraniCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France.
Karine DurandCancer Molecular Genetics Platform, Department of Pathology, CHU Dupuytren, Limoges, France. karine.durand@chu-limoges.fr.ORCID https://orcid.org/0000-0002-9738-3444

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA sequencing (RNA-Seq) is a next-generation sequencing method, routinely used in laboratories to detect abnormal transcripts with oncogenic activity after RNA extraction from formalin-fixed-paraffin-embedded (FFPE) samples of non-small-cell-lung cancers (NSCLC), then allowing targeting of the corresponding fusion kinase with adapted pharmacologic compounds in the clinical practice. Here, we provide a detailed protocol for total nucleic acid (i.e., RNA and DNA) extraction from FFPE samples and targeted RNA-Seq, by the FusionPlex

Indexed as

Carcinoma, Non-Small-Cell LungGene FusionHigh-Throughput Nucleotide SequencingLung NeoplasmsOncogene Proteins, FusionSequence Analysis, RNAHumansParaffin EmbeddingTissue FixationOncogene Proteins, FusionFFPEFusion transcriptNSCLCRNA extractionRNA-SeqWet lab process

Identifiers

PMID40699426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.